An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeTrial IDs
Phase IITreatmentActive18 and overTL139204
NCI-2015-00076, NCT00685204

Trial Description


Milataxel is a new taxane that may have several advantages over the currently available

taxanes. The current study is designed to determine the response rate of oral Milataxel in

patients with malignant Mesothelioma. The study specifically targets patients who have

recurring or progressive disease following previous chemotherapy.

Further Study Information

This is a non-randomized, multicenter, open label, single agent phase II study. Patients

with malignant mesothelioma that has recurred or progressed following chemotherapy, and who

qualify for this study, will receive milataxel 60 mg/m2 orally on Day 1 of a 21 day cycle.

If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for

the second and subsequent cycles. Patients will receive drug for a total of six cycles.

Milataxel administration in excess of six cycles will be permitted at the discretion of the

Investigator if patients have stable or responding disease.

Eligibility Criteria

Inclusion Criteria:

Patients must have histologically or cytologically confirmed malignant mesothelioma

for which they have received pemetrexed in combination with cisplatin as part of

chemotherapeutic regimen.

Prior cancer therapy with pemetrexed/cisplatin must have been completed at least 30

days prior to the first cycle of milataxel; prior radiotherapy (less than 25% of the

bone marrow) must have been completed at least 30 days prior to study enrollment.

Patients must have measurable disease by the Modified RECIST criteria

Patients must have a life expectancy of at least 12 weeks and an ECOG performance

status of 0, 1 or 2

Patients must be 18 years of age.

Patients must have adequate organ and system function.

Patients must be able to comply with the protocol treatments and procedures.

Patients with known brain metastases may be included in the study, providing they are

clinically stable.

Recovered from all acute toxicities caused by prior cancer therapies, except for


Exclusion Criteria:

Patients must not have received any other chemotherapeutic treatment for malignant

mesothelioma other than pemetrexed and a platinum agent such as cisplatin.

Patients with grade 2 or greater peripheral neuropathy.

Prior cancer therapies not completed within 30 days prior to the first cycle of

milataxel; radiotherapy completed less than 30 days prior to study enrollment;

patients not recovered from radiation-related toxicities; patients receiving any

concurrent anti-cancer therapy, including trastuzumab, bevacizumab or an

investigational agent while on-study; patients with greater than 2 prior radiotherapy


Patients with known sensitivity to alcohol.

Patients with significant intercurrent illnesses.

Patients with symptomatic CNS metastases.

Patients who have had major surgery within the past 14 days.

Patients who require or are likely to require any strong modifier of CYP450 activity

to be taken prior to milataxel administration

Patients who are receiving high dose steroids (more than a dexamethasone-equivalent

dose of 4 mg per day).

Patients with malabsorption syndrome, disease significantly affecting

gastrointestinal function, or major resection of the stomach or small bowel that

could affect absorption of the study drug.

Women who are pregnant or breastfeeding.

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

Taxolog, Inc.

    Trial Sites


    New York
    New York

    Columbia University/Herbert Irving Cancer Center

    Robert N. Taub
    Principal Investigator

    Link to the current record.
    NLM Identifier NCT00685204

    Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the record via the link above for more information about participating sites.